CCNU (Lomustine)

From Glioblastoma Treatments
Revision as of 05:09, 24 March 2024 by Lazy (talk | contribs) (Created page with "{{TreatmentInfo |drug_name=CCNU (Lomustine) |FDA_approval=Yes |used_for=Glioblastoma |clinical_trial_phase=Phase 3 (Germany) |common_side_effects=Hematological toxicity, nausea, vomiting, and pulmonary toxicity |OS_with=23 months median survival, with 47% at 2 years |usefulness_rating=4 |notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outco...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
Property Information
Drug Name CCNU (Lomustine)
FDA Approval Yes
Used for Glioblastoma
Clinical Trial Phase Phase 3 (Germany)
Clinical Trial Explanation Not specified
Common Side Effects Hematological toxicity, nausea, vomiting, and pulmonary toxicity
OS without Not specified
OS with 23 months median survival, with 47% at 2 years
PFS without Not specified
PFS with Not specified
Usefulness Rating 4
Usefulness Explanation Not specified
Toxicity Level Not specified
Toxicity Explanation Not specified

Notes: A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outcomes.


From Ben Williams Book: Not specified

Loading comments...
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=CCNU_(Lomustine)&oldid=106"